Vincent Delattre
About Vincent Delattre
Vincent Delattre is the VP of Business Development and Co-Founder at ONWARD, holding a PhD in Neurosciences from EPFL. He has received multiple entrepreneurial awards and played a significant role in advancing research and clinical studies in neural technologies.
Work at Onward
Vincent Delattre serves as the Vice President of Business Development and Co-Founder at ONWARD, a position he has held since 2020. In this role, he is responsible for managing the preparation of pilot clinical studies and research contracts with both academic and industrial partners. His work focuses on advancing the company's mission to develop innovative solutions for neurorehabilitation.
Education and Expertise
Vincent Delattre holds a PhD in Neurosciences from École Polytechnique Fédérale de Lausanne (EPFL), where his research centered on the impact of electrical stimulation on neural circuit re-organization. He also completed a Master’s project at the Laboratory of Neural Microcircuitry at EPFL. His educational background includes a specialization in Neurosciences within an Engineering degree from EPFL, and he completed his high school education at Centre International de Valbonne.
Background
Vincent Delattre has a diverse professional background that includes significant roles at EPFL. He worked as a PhD Candidate on the Human Brain Project from 2008 to 2014 and as a Post-Doctoral Researcher and Entrepreneur from 2013 to 2014. Additionally, he was involved in Health Technology Assessment (HTA) at EPFL and HEC from 2006 to 2007. His early experience includes a Master project at the Laboratory of Neural Microcircuitry from 2007 to 2008.
Achievements
Vincent Delattre has received multiple entrepreneurial awards and grants, including the Innogrant in 2013, Venture Kick I & II in 2013 and 2014, and the Hello Tomorrow Challenge Grand Prize in 2014. He played a key role in the 2016 Series A financing round for GTX Medical, which raised 36 million euros, and was instrumental in the 2019 merger between GTX and Neurorecovery Technology Inc. His contributions also include co-authoring the first clinical results published in the Nature journal in 2018, which demonstrated motor control recovery after complete paralysis.